Stepan Company (SCL) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly report (Form 10-Q) for Stepan Company for the period ended June 30, 2025. Stepan is a global producer of intermediate chemicals used in cleaning, personal care, and industrial applications, organized into three segments: Surfactants, Polymers, and Specialty Products.
Key Financial Metrics
| Metric | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Net Sales | $594.7M | $556.4M | $1,187.9M | $1,107.8M |
| Gross Profit | $71.9M | $69.6M | $147.3M | $139.8M |
| Operating Income | $18.0M | $18.7M | $46.3M | $38.8M |
| Net Income | $11.3M | $9.5M | $31.1M | $23.4M |
| Diluted EPS | $0.50 | $0.42 | $1.36 | $1.02 |
| Operating Cash Flow (YTD) | $18.1M | $71.1M | $18.1M | $71.1M |
| Total Debt | $658.0M | $625.4M | $658.0M | $625.4M |
| Cash & Equivalents | $88.9M | $124.7M | $88.9M | $124.7M |
Material Changes vs. Prior Period
- Revenue Growth: Q2 2025 net sales increased 7% year-over-year, driven by a 1% volume increase and higher average selling prices (pass-through of raw material costs). Foreign currency translation had a negative impact of $1.7M.
- Profitability: Operating income decreased 4% in Q2 2025 due to higher operating expenses, despite flat gross profit. However, YTD operating income increased 19%.
- Segment Performance:
- Surfactants: Sales up 8%, but operating income down 22% due to a $1.1M USEPA penalty and higher operating expenses.
- Polymers: Sales up 2%, operating income up 26% driven by volume growth and improved margins.
- Specialty Products: Sales up 22%, operating income down 28% due to order timing shifts in the pharmaceutical business.
- Working Capital: Operating cash flow declined significantly YTD ($18.1M vs $71.1M prior year) due to increased inventory build-up ($30.7M cash use) and higher receivables ($31.8M cash use) to support sales growth and tariff anticipation.
- Debt: Total debt increased by $32.6M to $658.0M, primarily due to the issuance of $75.0M in senior unsecured notes in May 2025.
Guidance, Outlook, and Risks
- Capital Expenditures: Management estimates total 2025 capital expenditures will range from $120.0M to $125.0M.
- Tax Legislation: A new U.S. tax act (H.R.1) signed July 4, 2025, is not reflected in Q2 results. Management does not anticipate a material impact on 2025 financial results.
- Environmental & Legal:
- The company accrued an additional $1.8M for remediation at the Elwood, Illinois (Millsdale) facility in Q2.
- Total environmental and legal accruals are $19.5M, with a possible loss range of $19.5M to $44.9M.
- A $1.1M USEPA penalty for FIFRA violations was paid in July 2025; the company is pursuing indemnification.
- Asset Sale: Stepan Philippines Quaternaries, Inc. assets are held for sale, with closing expected in H2 2025.
Investor Verification Checklist
- Inventory Build: Verify the rationale for the $30.7M increase in inventory (tariff anticipation, hurricane season safety stock, and new collective bargaining agreement preparation).
- USEPA Penalty: Monitor the status of indemnification claims regarding the $1.1M FIFRA penalty paid in July 2025.
- Environmental Accruals: Track potential changes to the $19.5M - $44.9M estimated loss range, particularly regarding the Millsdale facility remediation scope.
- Debt Covenants: Confirm continued compliance with the 3.50:1.00 interest coverage and net leverage ratios following the new debt issuance.
- Deferred Compensation: Note the volatility in deferred compensation expense ($1.8M expense in Q2 2025 vs $0.4M in Q2 2024) driven by mutual fund asset valuations.